Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease

Phytopharm

Status and phase

Completed

Phase 2

Conditions

Alzheimer's Disease

Treatments

Drug: PYM50028

Study type

Interventional

Funder types

Industry

Identifiers

NCT00130429

P58/09ME/03/04

Details and patient eligibility

About

The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At least 50 years of age
Diagnosis of possible or probable Alzheimer's disease
Mini mental state examination score at least 16
Good understanding of both written and verbal English
A recent head scan that is consistent with the diagnosis of Alzheimer's disease

Exclusion criteria

Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
Known to have another condition that is associated with dementia
Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)
Hormone replacement therapy started or changed within the previous 6 months
Received any investigational drugs within the previous 12 weeks